SCHEMBL6789216

SCHEMBL6789216

O=C(COc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCc3ccccn3)cc2)cc1)Nc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
LMNA P02545 3/20 0.46
HTT P42858 2/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNB4 P30926 2/20 0.46
CHRNA3 P32297 2/20 0.46
CHRNA4 P43681 2/20 0.46
SMO Q99835 2/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPT P10636 2/20 0.45
TDP1 Q9NUW8 2/20 0.44
PORCN Q9H237 2/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6792821 0.93 GAA (0.48) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6794937 0.92 NPC1 (0.48) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL7083610 0.90 NPC1 (0.46) SMN1; SMN2NPC1RAB9APOLBLMNA
SCHEMBL6792973 0.90 NPC1 (0.47) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6793672 0.89 PKM (0.45) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6793525 0.89 RAB9A (0.45) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6796259 0.89 NPC1 (0.50) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6792178 0.88 MAPT (0.50) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6795010 0.88 RAB9A (0.55) SMN1; SMN2NPC1RAB9APOLBGAA
SCHEMBL6791511 0.87 HTT (0.57) NPC1RAB9APOLBGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 SMN1; SMN2 2504/4885NPC1 64/4885RAB9A 3707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.